Advertisement


Jeremy S. Abramson, MD, on Non-Hodgkin Lymphoma: Results From the TRANSCEND NHL 001 Trial

2018 ASCO Annual Meeting

Advertisement

Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).



Related Videos

Lung Cancer

Geoffrey R. Oxnard, MD, on Lung Cancer: Results From the Circulating Cancer Genome Atlas Study

Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, discusses genome-wide sequencing for early-stage lung cancer detection from plasma cell–free DNA (Abstract LBA8501).

Multiple Myeloma

Aviva C. Krauss, MD, on Multiple Myeloma: Treatment Trials Analysis

Aviva C. Krauss, MD, of the U.S. Food and Drug Administration, discusses findings on an FDA analysis of immune-related adverse events and response to pembrolizumab in multiple myeloma (Abstract 8008).

Kidney Cancer

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on Metastatic RCC: Perspectives on the Carmena Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).

Pancreatic Cancer

Thierry Conroy, MD, on Pancreatic Cancer: Results From the PRODIGE 24 Trial

Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinomas (Abstract LBA4001).

Nancy Davidson: Serendipity and Purpose (with Allen S. Lichter, MD)

Allen S. Lichter, MD, ASCO’s former Chief Executive Officer, talks with Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, the 2018 recipient of the Visionary Leader Award, named for Dr. Lichter.

Advertisement

Advertisement




Advertisement